Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with immunoglobulin G-mediated autoimmune diseases. The company became publicly traded in 2019 through a business combination with Health Sciences Acquisitions Corporation, a special purpose acquisition company sponsored by HSAQ Holdings LLC. Immunovant's lead program centers on batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor. The company filed an 8-K with the SEC on September 3, 2026, accession number 0001764013-26-000106, disclosing material corporate developments. Immunovant operates in the biopharmaceutical sector and remains active on the Nasdaq exchange. For complete filing data, pipeline timelines, and SPAC-origin analytics on Immunovant and hundreds of other companies, sign up for full access at SpacDesk.